Literature DB >> 27839983

Gaucheromas: When macrophages promote tumor formation and dissemination.

Margarita Ivanova1, Renuka Pudi Limgala1, Erk Changsila2, Ravi Kamath3, Chidima Ioanou1, Ozlem Goker-Alpan4.   

Abstract

Deficiency of the lysosomal enzyme, β-glucocerebrosidase, and accumulation of its substrate in cells of the reticuloendothelial system affects multiple organ systems in patients with Gaucher disease (GD). Lipid laden macrophages turn into Gaucher cells (GC) which are the pathological characteristic of GD. GC focally accumulate in the liver, spleen and at extraosseous sites to form benign lesions called Gaucheromas. Gaucheromas pose diagnostic and therapeutic challenges. We studied the pathophysiology of extraosseous Gaucheroma formation in a cohort of patients with GD. Among 63 patients followed at a single center, 3 patients with genotypes L444P/L444P and N370S/N370S, were diagnosed with extraosseous Gaucheromas. Flow cytometry revealed a higher expression of CD16+/CCR4+ non-classical monocytes in blood of GD patients who have developed Gaucheromas. A biopsy showed infiltration of GC, which reactivity against CD163, CD68 and VEGF. The cell proliferative marker Ki67 and CCL2, a factor anti-tumor activity, were negative. Our study indicates that extraosseous Gaucheromas are comprised of cellular elements with characteristics of tumor-associated macrophages, the major players in cancer related inflammation. The occurrence of non-classical CD16+/CCR4+ monocytes reflect the underlying cause for the accumulation of the macrophages capable of migrating to distant sites outside the reticuloendotheial system, and giving rise to tumor-like Gaucheromas.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GBA; Gaucher disease; Gaucheroma; Glucosylceramidase beta; Macrophages; Tumor

Mesh:

Substances:

Year:  2016        PMID: 27839983     DOI: 10.1016/j.bcmd.2016.10.018

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  7 in total

1.  ACE phenotyping in Gaucher disease.

Authors:  Sergei M Danilov; Victoria E Tikhomirova; Roman Metzger; Irina A Naperova; Tatiana M Bukina; Ozlem Goker-Alpan; Nahid Tayebi; Nurshat M Gayfullin; David E Schwartz; Larisa M Samokhodskaya; Olga A Kost; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2018-02-17       Impact factor: 4.797

Review 2.  Role of lysosomes in physiological activities, diseases, and therapy.

Authors:  Ziqi Zhang; Pengfei Yue; Tianqi Lu; Yang Wang; Yuquan Wei; Xiawei Wei
Journal:  J Hematol Oncol       Date:  2021-05-14       Impact factor: 17.388

3.  Progressive macrophage accumulation in lysosomal acid lipase deficiency.

Authors:  Patryk Lipiński; Joanna Cielecka-Kuszyk; Anna Bożkiewicz-Kasperczyk; Barbara Perkowska; Elżbieta Jurkiewicz; Anna Tylki-Szymańska
Journal:  Mol Genet Metab Rep       Date:  2020-05-01

4.  Very rare condition of multiple Gaucheroma: A case report and review of the literature.

Authors:  Szu-Yin Tseng; Dau-Ming Niu; Tzu-Hung Chu; Yi-Chen Yeh; Man-Hsu Huang; Tsui-Feng Yang; Hsuan-Chieh Liao; Chuan-Chi Chiang; Hui-Chen Ho; Wen-Jue Soong; Chia-Feng Yang
Journal:  Mol Genet Metab Rep       Date:  2019-05-09

5.  Very rare condition of multiple Gaucheroma: A case report and review of the literature.

Authors:  Szu-Yin Tseng; Dau-Ming Niu; Tzu-Hung Chu; Yi-Chen Yeh; Man-Hsu Huang; Tsui-Feng Yang; Hsuan-Chieh Liao; Chuan-Chi Chiang; Hui-Chen Ho; Wen-Jue Soong; Chia-Feng Yang
Journal:  Mol Genet Metab Rep       Date:  2019-07-12

6.  The natural history of type 2 Gaucher disease in the 21st century: A retrospective study.

Authors:  Tamanna Roshan Lal; Gurpreet K Seehra; Alta M Steward; Chelsie N Poffenberger; Emory Ryan; Nahid Tayebi; Grisel Lopez; Ellen Sidransky
Journal:  Neurology       Date:  2020-08-06       Impact factor: 9.910

7.  TRAP5b and RANKL/OPG Predict Bone Pathology in Patients with Gaucher Disease.

Authors:  Margarita Ivanova; Julia Dao; Lauren Noll; Jacqueline Fikry; Ozlem Goker-Alpan
Journal:  J Clin Med       Date:  2021-05-20       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.